Neostigmine/glycopyrronium bromide
| Combination of | |
|---|---|
| Neostigmine | Cholinesterase inhibitor |
| Glycopyrronium bromide | Antimuscarinic agent |
| Clinical data | |
| Trade names | Prevduo |
| Other names | Neostigmine methylsulfate/glycopyrrolate, glycopyrronium bromide/neostigmine metilsulfate |
| AHFS/Drugs.com | Micromedex Detailed Consumer Information |
| License data | |
| Routes of administration | Intravenous |
| ATC code | |
| Legal status | |
| Legal status | |
Neostigmine/glycopyrronium bromide, sold under the brand name Prevduo , is a fixed-dose combination medication used for the reversal of the effects of non-depolarizing neuromuscular blocking agents after surgery.[2] It contains neostigmine as the methylsulfate, a cholinesterase inhibitor, and glycopyrronium bromide, an antimuscarinic agent.[2]
Neostigmine/glycopyrronium bromide was approved for medical use in the United Kingdom in 2007,[1] and in the United States in February 2023.[3]
Medical uses
Neostigmine/glycopyrronium bromide is indicated for the reversal of the effects of non-depolarizing neuromuscular blocking agents after surgery, while decreasing the peripheral muscarinic effects (e.g., bradycardia and excessive secretions) associated with cholinesterase inhibition following non-depolarizing neuromuscular blocking agent reversal administration.[3]
References
- 1 2 "Glycopyrronium Bromide and Neostigmine Metilsulfate 0.5mg/2.5mg per ml Solution for Injection - Summary of Product Characteristics (SmPC)". (emc). 12 November 2018. Archived from the original on 7 August 2022. Retrieved 25 February 2023.
- 1 2 3 "Prevduo- neostigmine methylsulfate and glycopyrrolate injection". DailyMed. 10 April 2024. Retrieved 17 April 2025.
- 1 2 Roca R (23 February 2023). "Prevduo Approval Letter" (PDF). U.S. Food and Drug Administration. Archived from the original (PDF) on 26 February 2023.
This article incorporates text from this source, which is in the public domain.